Fesoterodine Fumarate Patent Expiration
Fesoterodine Fumarate is Used for treating overactive bladder symptoms such as urge urinary incontinence, urgency, and frequency. It was first introduced by Pfizer Inc
Fesoterodine Fumarate Patents
Given below is the list of patents protecting Fesoterodine Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Toviaz |
US7807715 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz |
US8088398 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz |
US8501723 (Pediatric) | Pharmaceutical compositions comprising fesoterodine | Dec 07, 2027 | Pfizer |
| Toviaz | US7807715 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz | US8088398 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz | US8501723 | Pharmaceutical compositions comprising fesoterodine | Jun 07, 2027 | Pfizer |
| Toviaz |
US6858650 (Pediatric) | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan 03, 2023
(Expired) | Pfizer |
| Toviaz | US6858650 | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul 03, 2022
(Expired) | Pfizer |
| Toviaz | US7384980 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US7855230 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US7985772 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
| Toviaz | US8338478 | Derivatives of 3,3-diphenylpropylamines |
May 11, 2019
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fesoterodine Fumarate's patents.
Latest Legal Activities on Fesoterodine Fumarate's Patents
Given below is the list recent legal activities going on the following patents of Fesoterodine Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 28 Aug, 2023 | US7985772(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8088398 |
| Maintenance Fee Reminder Mailed Critical | 13 Mar, 2023 | US7985772(Litigated) |
| Expire Patent Critical | 23 Jan, 2023 | US7855230(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 08 Aug, 2022 | US7855230(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Mar, 2022 | US7807715 |
| Expire Patent Critical | 01 Feb, 2021 | US8338478(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jan, 2021 | US8501723 |
| Maintenance Fee Reminder Mailed Critical | 17 Aug, 2020 | US8338478(Litigated) |
| Expire Patent Critical | 13 Jul, 2020 | US7384980(Litigated) |
Fesoterodine Fumarate's Family Patents
Explore Our Curated Drug Screens
Fesoterodine Fumarate Generic API Manufacturers
Several generic applications have been filed for Fesoterodine Fumarate. The first generic version for Fesoterodine Fumarate was by Alkem Laboratories Ltd and was approved on Dec 10, 2015. And the latest generic version is by Hetero Labs Ltd Unit V and was approved on Jan 9, 2024.
Given below is the list of companies who have filed for Fesoterodine Fumarate generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 8MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
| 4MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
2. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
| 8MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
3. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Prescription | ORAL | AB | Jan 4, 2023 |
| 8MG | tablet, extended release | Prescription | ORAL | AB | Jan 4, 2023 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
4. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 8MG | tablet, extended release | Prescription | ORAL | AB | Dec 10, 2015 |
| 4MG | tablet, extended release | Prescription | ORAL | AB | Dec 10, 2015 |
5. AMNEAL PHARMS NY
Amneal Pharmaceuticals Of Ny Llc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Amneal Pharms Ny.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Prescription | ORAL | AB | Jan 4, 2023 |
| 8MG | tablet, extended release | Prescription | ORAL | AB | Jan 4, 2023 |
6. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Ani Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
| 8MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 4, 2023 |
7. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Prescription | ORAL | AB | Feb 17, 2017 |
| 8MG | tablet, extended release | Prescription | ORAL | AB | Feb 17, 2017 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
8. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 5, 2023 |
| 8MG | tablet, extended release | Discontinued | ORAL | N/A | Jan 5, 2023 |
9. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 8MG | tablet, extended release | Prescription | ORAL | AB | Aug 13, 2019 |
| 4MG | tablet, extended release | Prescription | ORAL | AB | Aug 13, 2019 |
10. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 8MG | tablet, extended release | Prescription | ORAL | AB | Jan 9, 2024 |
| 4MG | tablet, extended release | Prescription | ORAL | AB | Jan 9, 2024 |
11. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Fesoterodine Fumarate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | tablet, extended release | Prescription | ORAL | AB | Oct 3, 2017 |
| 8MG | tablet, extended release | Prescription | ORAL | AB | Oct 3, 2017 |